Evidence map›Paper›PMID 41343102›Full record

ArticleMedical oncology (Northwood, London, England)2025

Survivin targeting triple-fusion vaccine

Ambreen Rashid, Anuja Krishnan, Sarika Gupta, Jagdish C Gupta, G P Talwar

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ambreen RashidTalwar Research Foundation, E-8, Neb Valley, New Delhi, 110068, India.ORCID http://orcid.org/0009-0009-8653-4559
Anuja KrishnanJamia Hamdard, Hamdard Nagar, New Delhi, 110062, India.ORCID http://orcid.org/0000-0001-6538-2044
Sarika GuptaNational Institute of Immunology, New Delhi, 110067, India.ORCID http://orcid.org/0000-0002-3054-0337
Jagdish C GuptaTalwar Research Foundation, E-8, Neb Valley, New Delhi, 110068, India. jcgupta@outlook.com.ORCID http://orcid.org/0000-0002-9456-0097
G P TalwarTalwar Research Foundation, E-8, Neb Valley, New Delhi, 110068, India.ORCID http://orcid.org/0000-0002-3421-1303

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survivin, an anti-apoptotic protein, plays a pivotal role in cancer progression by disrupting the balance between cell division and apoptosis. We have developed and characterized an anti-Survivin vaccine designed as a triple fusion protein to enhance immunogenicity. In this study, we have evaluated the vaccine's efficacy in reducing tumor growth using a Survivin expressing 4T1 pre-clinical mouse model of triple-negative breast cancer (TNBC), which is difficult to treat due to its heterogeneous microenvironment, aggressive nature, poor prognosis, and high relapse rates. The recombinant

Indexed as

Cancer VaccinesDendritic CellsInhibitor of Apoptosis ProteinsSurvivinTriple Negative Breast NeoplasmsAnimalsApoptosisCell Line, TumorDisease Models, AnimalFemaleHumansMiceMice, Inbred BALB CBirc5 protein, mouseCancer VaccinesInhibitor of Apoptosis ProteinsSurvivinBreast cancerDendritic cellsImmunotherapySurvivinTNBC

Identifiers

PMID41343102

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.